PR Newswire - November 1, 1995

"Among the more pressing needs in the area of HIV therapy are compounds that act against new viral targets," remarked Michael McGrath, M.D., Ph.D., Associate Professor of Laboratory Medicine, University of California at San Francisco, a co-author of the study. "AR-177 appears to block the viral activity of HIV integrase, rather than reverse transcriptase or HIV protease. This activity may be complementary to compounds which operate by inhibiting these commonly targeted enzymes." Dr. McGrath cautioned that these laboratory results are still early and must be confirmed in clinical tests, which have just recently begun in humans.

HIV integrase is an enzyme that the virus uses to insert its replicated genetic material (DNA) into the host chromosome or DNA. In the new studies, the collaborating researchers demonstrated that AR-177 inhibited this enzyme. Most other HIV therapeutic drugs act by inhibiting either viral reverse transcriptase -- which HIV-1 uses to replicate its genetic code -- or viral protease, which HIV-1 uses to make its protective protein coat. AR-177 is a short oligonucleotide made up entirely of the nucleotides deoxyguanosine and thymidine linked by a phosphodiester backbone. Internucleoside bonds at the two ends of the molecule are chemically modified to help stabilize the compound against attack by cellular enzymes. The molecule also folds itself into a defined three-dimensional structure which gives AR-177 its potent activity.

The researchers reached their results by infecting several types of cells, including peripheral blood cells (PBMCs and PBLs) and several laboratory cell lines, with HIV-1. The cells were treated with either AZT or AR-177. The cell cultures were then analyzed for viral proliferation at various lengths of time by measuring both the levels of viral p24 antigen production in the culture medium or the amount of intracellular viral DNA. The effect of AR-177 on PBLs was also analyzed by measuring their levels of CD4 and CD8 antigen expression in culture.

The compound's three-dimensional structure appears to contribute to its mechanism of action, its long half-life and an extended duration of activity. In mouse systems, AR-177 had a half-life of days. In culture assays, viral production was halted for more than 21 days following four days of AR-177 treatment. By comparison, AZT, which has a half-life of hours, halted viral production for only two additional days following a four-day AZT treatment. The paper also reported that studies with human immune cells show no observable toxicity from high in vitro doses of AR- 177.

"This compound is the first new molecular agent to emerge from the Aronex research pipeline," said James Chubb, Ph.D., President of Aronex Pharmaceuticals. "We are focused on moving it rapidly through clinical development, and towards that end we recently initiated a Phase I study in HIV patients."

Clinical trials were begun in October by James Kahn, M.D., Associate Director of the AIDS Program and Assistant Professor of Medicine at the University of California at San Francisco, at San Francisco General Hospital. The first clinical study is an open label, dose-escalating trial using single doses of AR-177 to determine the toxicity and pharmacokinetics of the compound in HIV-1-positive patients. A repeat dose study will be started at the conclusion of the single escalating dose trial. The first patient was dosed on October 23, 1995.

The study reported today resulted from the collaboration of Robert Rando, Ph.D., Joshua Ojwang, Ph.D., and coworkers at Aronex Pharmaceuticals, Erik De Clercq, M.D., Ph.D., and coworkers at the Katholieke Universiteit Leuven, Yves Pommier, M.D., Ph.D., and coworkers at the National Cancer Institute, Michael McGrath, M.D., Ph.D., at the University of California at San Francisco and Robert Buckheit, Ph.D., and coworkers at the Southern Research Institute.

Aronex Pharmaceuticals, Inc. is developing and commercializing innovative pharmaceuticals for treating cancer and infectious diseases. Aronex has several products in clinical development including Nystatin(LF) for the treatment of systemic fungal infections, Annamycin(LF) for the treatment of solid tumors and AR-177 for HIV infection. The Company has a collaboration with Genzyme Corporation to develop Tretinoin(LF) for the treatment of Kaposi's sarcoma and acute promyelocytic leukemia.

CONTACT: James Chubb, Ph.D., President of Aronex Pharmaceuticals, Inc., 713-367-1666, or Michelle Linn, Senior Account Executive of Feinstein Partners Inc., 617-577-8110/ 08:23 EST

Copyright (c) 1995/PR NewsWire. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through the Permissions Desk, PR Newswire, 810 Seventh Avenue, New York, NY 10019.
951101
PR951101

Always watch for outdated information. This article first appeared in 1995. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1995. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .